SCHEMBL2908176

SCHEMBL2908176

COC(=O)c1cccc(NC(c2cccnc2)c2ccc(F)c(O[C@@H]3CCOC3)c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 6/20 0.38
ITK Q08881 4/20 0.38
GRM4 Q14833 1/20 0.37
ABL1 P00519 1/20 0.37
BCR P11274 1/20 0.37
SRC P12931 1/20 0.37
RAB9A P51151 1/20 0.35
PDE4D Q08499 4/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
EPHX2 P34913 1/20 0.35
ALDH1A1 P00352 1/20 0.35
KRAS P01116 1/20 0.35
SOS1 Q07889 1/20 0.35
PFKFB3 Q16875 1/20 0.35
PFKFB4 Q16877 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2909625 0.77 TP53 (0.47) RAB9AALDH1A1KDM4EMAPT
SCHEMBL2908178 0.76 PDE4D (0.41) EGFRITKGRM4PDE4DPDE4A
SCHEMBL2908182 0.76 PDE4D (0.41) EGFRITKGRM4PDE4DPDE4A
SCHEMBL2907262 0.75 PDE4D (0.38) GRM4PDE4DPDE4APDE4BPDE4C
SCHEMBL2902486 0.75 PDE4D (0.38) GRM4PDE4DPDE4APDE4BPDE4C
SCHEMBL2909821 0.72 LMNA (0.45) RAB9APDE4DALDH1A1KDM4EMAPT
SCHEMBL3120970 0.71 RAB9A (0.39) RAB9APDE4AEPHX2
SCHEMBL2902818 0.70 PDE4A (0.46) PDE4DPDE4APDE4BPDE4C
SCHEMBL2903512 0.69 MRGPRX4 (0.41) ABL1BCRRAB9APDE4DPDE4A
SCHEMBL2909129 0.68 KMT2A (0.45) RAB9APDE4DALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1692109-B1 PHOSPHODIESTERASE 4 INHIBITORS, INCLUDING N-SUBSTITUTED DIARYLAMINE ANALOGS MEMORY PHARM CORP (US) 2010-08-18 EP disclosed
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs MEMORY PHARMACEUTICAL CORPORATION 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222207-A1 Phosphodiesterase 4 inhibitors, including N-substituted diarylamine analogs PDE4A, PDE4B, PDE3B EGFR 4663/4885ITK 4245/4885GRM4 1872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.